Combining immunological and androgen-directed approaches: An emerging concept in prostate cancer immunotherapy

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 258-265

  Antonarakis, Emmanuel S ^a   Drake, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

androgen ablation; immune checkpoints; immunotherapy; prostate cancer; vaccine

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; IPILIMUMAB; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SIPULEUCEL T;

ANDROGEN THERAPY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; T LYMPHOCYTE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CANCER VACCINES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; MALE; POXVIRIDAE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS; VACCINES, DNA; VIRAL VACCINES;

EID: 84859877124     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835205a0     Document Type: Review

References (36)

1. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364:2055-2058.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512. (Pubitemid 39315317)
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
4. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
5. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
6. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8:587-594. (Pubitemid 46995621)
7. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446.
8. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7:239-249. (Pubitemid 40568683)
9. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007; 12:4957-4971.
10. May KF Jr, Gulley JL, Drake CG, et al. Prostate cancer immunotherapy. Clin Cancer Res 2011; 17:5233-5238.
11. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a Poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-674.
12. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010; 20:241-246.
13. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001; 98:14565-14570. (Pubitemid 33121432)
14. Gannon PO, Poisson AO, Delvoye N, et al. Characterization of the intraprostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348:9-17.
15. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109:32-39.
16. Koh YT, Gray A, Higgins SA, et al. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009; 69:571-584.
17. Antonarakis ES, Kibel AS, Lin DW, et al. Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy on immune markers in prostate cancer patients with a rising PSA after primary therapy [abstract]. J Clin Oncol 2011; 29:189.
18. Madan RA, Arlen PM, Mohebtash M, et al. ProstVac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009; 18:1001-1011.
19. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-1105.
20. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008; 14:4526-4531.
21. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001. (Pubitemid 351872317)
22. Alam S, McNeel DG. DNA vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2010; 9:731-745.
23. Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33:639-647.
24. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27:425-430.
25. Small EJ, Reese DM, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999; 5:1738-1744. (Pubitemid 29334454)
26. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37:533-546.
27. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer. Preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37:430-439.
28. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17:6958-6962.
29. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
30. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
31. Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab alone and in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer [abstract]. J Clin Oncol 2008; 26:5004.
32. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69:609-615.
33. Granberg C, Thompson RH, Quevedo JF, et al. Down-staging of locallyadvanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy [abstract]. J Clin Oncol 2009; 27:16103.
34. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-327.
35. Tagawa ST, Beltran H, Vallabhajosula S, et al. Antiprostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010; 116:1075-1083.
36. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specificmembrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23:4591-4601. (Pubitemid 46224061)